Navigation Links
Third-party blood stem cell transplantation as a factor to impact on poor graft function
Date:3/18/2013

>One unanswered question, said the researchers, was whether the immunosuppressive properties of MSCs are an important factor that could have a favorable impact on potential problems such as an increased risk of infection or tumor relapse following cell transplantation.

"Although six of 20 patients died from infections within the first 100 days of MSC transplantation, we could not safely conclude that MSCs increased the incidence of infections other than Epstein-Barr," they wrote.

In conclusion, the researchers noted that "clinical applications of human MSCs are evolving rapidly with goals of improving hematopoietic engraftment and preventing GVHD after allogenic hematopoietic stem cell transplantation."

"This study highlights the potential impact of allogeneic mesenchymal stem cell transplants as an adjunctive therapy for hematopoietic stem cell transplantation to reduce the likelihood of the patient developing graft versus host disease after exhibiting risk factors for poor functioning of the grafted cells" said Dr. Paul R. Sanberg, distinguished professor at the Center of Excellence for Aging and Brain Repair, University of South Florida.
'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Page: 1 2

Related biology news :

1. White blood cells found to play key role in controlling red blood cell levels
2. Prenatal exposure to pesticide DDT linked to adult high blood pressure
3. Temp-controlled nanopores may allow detailed blood analysis
4. Omega-3s from fish vs. fish oil pills better at maintaining blood pressure in mouse model
5. Stressed proteins can cause blood clots for hours
6. Study uncovers enzymes double life, critical role in cancer blood supply
7. Manchester patients take part in pioneering heart attack blood test trial
8. Blood vessels sniff gut microbes to regulate blood pressure
9. Childhood blood lead levels rise and fall with exposure to airborne dust in urban areas
10. Blood is thicker than water -- and blood plasma is, too
11. Rice University lab show how blood vessels regroup after stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... A thin polymer bio-film that seals surgical wounds could make ... thick, the film is placed on a surgical wound and ... enough to meld it and the tissue, thus perfectly sealing ... is extracted from crab shells and has Food and Drug ...
... greenhouse gas, is emitted in great quantities as bubbles from ... of these bubbles dissolve into the ocean, but the fate ... of California, Santa Barbara have discovered that only one percent ... news for the Earth,s atmosphere. Coal Oil Point (COP), ...
... Center for Ecological Analysis and Synthesis have developed a ... across landscapes. Their approach could give managers a better ... which are crucial to protecting biodiversity. There are ... connectivity, said Brad McRae, head of the project. Its ...
Cached Biology News:Surgery without stitches 2Scientists find good news about methane bubbling up from the ocean floor 2Model connects circuit theory to wildlife corridors 2
(Date:7/29/2015)... ... 2015 , ... Finding gooey or crusty material in the corner of your ... considerable number of terms in popular use to describe it, ophthalmologists call it “gound” ... mucus, blood cells, skin cells and dust, but until now there has been virtually ...
(Date:7/29/2015)... ... 2015 , ... Rainbow Scientific, Inc. (RSI), a North American ... BI’s line of human mesenchymal stem cell (hMSC) differentiation media, MSC go ... complete system for multipotency evaluation of hMSCs and reliable induction of hMSCs into ...
(Date:7/28/2015)... ... , ... Strong Animals™ announced today that research conducted by South Dakota State ... ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, FL showed feed additive Stay ... content. Also, feed containing Stay Strong™ for Dairy Cows took longer than 7.7 hours ...
(Date:7/28/2015)... BILLERICA, Mass. , July 28, 2015 /PRNewswire/ ... for measuring cell metabolism, is the provider of ... utilized across all disease research areas. As the ... revealed, exploration into cell metabolism is escalating rapidly.   ... been published by the Nature Publishing Group (NPG) ...
Breaking Biology Technology:What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... May 17, 2011 Amgen (NASDAQ: AMGN ... 3 trial (,147) demonstrating that XGEVA™ (denosumab) significantly increased ... men with castrate-resistant metastatic prostate cancer that has not ... study were presented for the first time today in ...
... DIEGO, May 17, 2011 P ... that it has submitted a Biologics Master File (BMF) to ... grade CRM197 carrier protein to support the development of conjugate ... Proteins is supplying cGMP grade CRM197 carrier protein to multiple ...
... /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: ... "Company"), a developer, manufacturer and distributor of botanical ... China, today announced that the Company successfully showcased ... ("the fair") recently held in Chengdu, China. ...
Cached Biology Technology:Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 2Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 3Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 4Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 5Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 6Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 7Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 8Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 9Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 2China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 3
... antibody raised against a partial recombinant IFNA2. ... partial recombinant protein is produced in E. coli. ... IU/ mg. OMIM: 147562, ... Lot Number: MM951100564 MA Code: ...
... V, is used to coat the inner wall ... the source of the DNA that enters target ... gun. The station includes a tubing support cylinder, ... Nalgene nitrogen regulator hose, two 0.1875 inch barb-to-male ...
... Microarray Hybridization Wash Pack provides ... microarray slides. Preparation Quality Clarifier: Ready-to-use ... use with SigmaScreen(tm) APS Coated Slides ... Microarray Hybridization Blocking Buffer: 1L ...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
Biology Products: